Fitbit, Inc. (NYSE:FIT) Buying London-Based Smartwatch Maker Vector- American Shared Hospital Services (AMS)

Fitbit, Inc. (NYSE:FIT) [Trend Analysis] considering as most desiring stocks in active trading lead, shares shows upbeat performance surged after opening to traded at $7.41 with volume of 709687 shares. San Francisco-based, Fitbit (FIT) reported that it was buying London-based smartwatch maker Vector. The news comes a little over a month after Fitbit acquired (and closed) Palo Alto-based smartwatch maker Pebble.Vector was founded in 2013 by two professors from University Politehnica of Bucharest who raised an estimated $12 million in capital to produce a smartwatch with a 30-day battery. Vector sells two watches, the Luna and Meridian, which start around $300 each.

Vector says it will honor existing warranties and continue to provide technical support to existing consumers, but have no plans to produce additional hardwareor software. “We believe this is an important milestone as a moment when we will start building other new and amazing products, features and experiences, incorporating our unique technology and knowhow with Fitbit’s experience and global community,” Vector said on its site.

FIT is ahead its 52-week low with 2.89%and going down from its 52-week high price with -65.73%. The company’s shares performance for the last one month was -7.45% and -7.68% in the previous week. As the revenues measures, firm has operation margin of 8.00% in the following twelve months with net profit margin of positive 4.30%. The Company showed a positive 4.30% in the net profit margin.

American Shared Hospital Services (NYSE:AMS) [Trend Analysis] swings ardently in active trading session; it plummets of -4.27% to close at $3.92.

The stock price of firm is moving up from its 20 days moving average with 18.31% and remote isolated positively from 50 days moving average with 21.55%. (Full [FREE Analysis] of NYSE:AMS And Be Sure To Notice The Intermediate Period)

Moving toward the volatility measures, the price volatility of stock was 8.81% for a week and 5.09% for a month as well as price volatility’s Average True Range for 14 days was 0.18. The beta, which indicates risk in relegation to the market, remained 0.71. The firm past twelve months price to sales ratio was 1.25. As far as the returns are concern, the return on equity was recorded as 3.70% and return on investment was -1.40% while its return on asset stayed at 1.30%.

For latest Market Updates Subscribes Here


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *